Draft FDA Guidance for COCCIDIOIDOMYCOSIS

David Larwood, CEO of VFS, summed it up at the Cocci FDA workshop in 2020: “When the market opportunity is limited, finding investment becomes the key issue”.  He mentioned other problems as well: “Very low patient numbers for disseminated disease, prolonged therapy, NI trial design, definition of clinical outcome”.[1] Clearly, Continue reading Draft FDA Guidance for COCCIDIOIDOMYCOSIS

MUCH ADO ABOUT NOTHING: Covid-19 Vaccination for Healthy Children

Oh, what a disaster: all the ACIP members were replaced for no good reason, the best and the brightest.  Now children will die as incompetence rules supreme.  The CDC’s guidance on Covid vaccination of healthy kids is being ignored, being made light of and challenged.  We are looking at governmental Continue reading MUCH ADO ABOUT NOTHING: Covid-19 Vaccination for Healthy Children

The 10 x ’20 Initiative – A Retrospective

It started all so well with fanfare and great expectations. Fifteen years ago, the 10 x ’20 initiative got underway. Its goals were spelled out clearly: To ‘Pursue a Global Commitment to Develop 10 New Antibacterial Drugs by 2020 ’[3].  It was driven by ID clinicians and by antibiotic developers concerned Continue reading The 10 x ’20 Initiative – A Retrospective